中国医药
中國醫藥
중국의약
CHINA MEDICINE
2009年
1期
5-7
,共3页
冯素玲%李建国%罗泽如%颛孙永勋%李依群
馮素玲%李建國%囉澤如%顓孫永勛%李依群
풍소령%리건국%라택여%전손영훈%리의군
肺癌%调节性T细胞%生物学检测
肺癌%調節性T細胞%生物學檢測
폐암%조절성T세포%생물학검측
Lung cancer%Regulatory T-Lymphocytes%Biological monitoring
目的 研究肺癌患者外周血CD4+CD25+调节性T细胞(Treg)的比例变化,探讨其与肺癌的临床分期、病理类型及组织学分化程度的相关性.方法 采用流式细胞术检测78例肺癌患者(肺癌组)和30例健康对照者(健康对照组)外周血CD4+CD25+Treg占CD4+T细胞的比例.结果 肺癌组外周血CD4+CD25+Treg占CD4+T细胞的比例为(21.07±5.26)%,与健康对照组(10.04±2.75)%比较,差异有统计学意义(P＜0.05);Ⅲ、Ⅳ期肺癌患者外周血CD4+CD25+Treg比例分别为(22.46±4.35)%、(24.35±6.20)%,显著高于Ⅰ期+Ⅱ期肺癌患者(12.89±3.19)%及健康对照组(10.04±2.75)%相比,差异有统计学意义(P＜0.05);鳞癌、腺癌、小细胞肺癌患者外周血CD4+CD25+Treg比例分别为(20.75±4.85)%、(21.52±5.26)%、(19.20±6.41)%,与健康对照组比较,差异均有统计学意义(P＜0.05),但不同病理类型的肺癌患者间外周血CD4+CD25+Treg比较,差异无统计学意义(P＞0.05);高分化、中分化、低分化肺癌患者外周血CD4+CD25+Treg比例分别为(20.36±3.12)%、(21.11±4.67)%、(21.30±5.75)%,显著高于对照组(P＜0.05),但不同分化程度的各肺癌者间比较,差异无统计学意义(P＞0.05).结论 肺癌患者外周血CD4+CD25+Treg水平明显升高,且与肺癌的进展密切相关,但与病理类型、组织学分化程度无关.
目的 研究肺癌患者外週血CD4+CD25+調節性T細胞(Treg)的比例變化,探討其與肺癌的臨床分期、病理類型及組織學分化程度的相關性.方法 採用流式細胞術檢測78例肺癌患者(肺癌組)和30例健康對照者(健康對照組)外週血CD4+CD25+Treg佔CD4+T細胞的比例.結果 肺癌組外週血CD4+CD25+Treg佔CD4+T細胞的比例為(21.07±5.26)%,與健康對照組(10.04±2.75)%比較,差異有統計學意義(P＜0.05);Ⅲ、Ⅳ期肺癌患者外週血CD4+CD25+Treg比例分彆為(22.46±4.35)%、(24.35±6.20)%,顯著高于Ⅰ期+Ⅱ期肺癌患者(12.89±3.19)%及健康對照組(10.04±2.75)%相比,差異有統計學意義(P＜0.05);鱗癌、腺癌、小細胞肺癌患者外週血CD4+CD25+Treg比例分彆為(20.75±4.85)%、(21.52±5.26)%、(19.20±6.41)%,與健康對照組比較,差異均有統計學意義(P＜0.05),但不同病理類型的肺癌患者間外週血CD4+CD25+Treg比較,差異無統計學意義(P＞0.05);高分化、中分化、低分化肺癌患者外週血CD4+CD25+Treg比例分彆為(20.36±3.12)%、(21.11±4.67)%、(21.30±5.75)%,顯著高于對照組(P＜0.05),但不同分化程度的各肺癌者間比較,差異無統計學意義(P＞0.05).結論 肺癌患者外週血CD4+CD25+Treg水平明顯升高,且與肺癌的進展密切相關,但與病理類型、組織學分化程度無關.
목적 연구폐암환자외주혈CD4+CD25+조절성T세포(Treg)적비례변화,탐토기여폐암적림상분기、병리류형급조직학분화정도적상관성.방법 채용류식세포술검측78례폐암환자(폐암조)화30례건강대조자(건강대조조)외주혈CD4+CD25+Treg점CD4+T세포적비례.결과 폐암조외주혈CD4+CD25+Treg점CD4+T세포적비례위(21.07±5.26)%,여건강대조조(10.04±2.75)%비교,차이유통계학의의(P＜0.05);Ⅲ、Ⅳ기폐암환자외주혈CD4+CD25+Treg비례분별위(22.46±4.35)%、(24.35±6.20)%,현저고우Ⅰ기+Ⅱ기폐암환자(12.89±3.19)%급건강대조조(10.04±2.75)%상비,차이유통계학의의(P＜0.05);린암、선암、소세포폐암환자외주혈CD4+CD25+Treg비례분별위(20.75±4.85)%、(21.52±5.26)%、(19.20±6.41)%,여건강대조조비교,차이균유통계학의의(P＜0.05),단불동병리류형적폐암환자간외주혈CD4+CD25+Treg비교,차이무통계학의의(P＞0.05);고분화、중분화、저분화폐암환자외주혈CD4+CD25+Treg비례분별위(20.36±3.12)%、(21.11±4.67)%、(21.30±5.75)%,현저고우대조조(P＜0.05),단불동분화정도적각폐암자간비교,차이무통계학의의(P＞0.05).결론 폐암환자외주혈CD4+CD25+Treg수평명현승고,차여폐암적진전밀절상관,단여병리류형、조직학분화정도무관.
Objective To evaluate the proportion of CD4+CD25+regulatory T cells(Treg)in peripheral blood of patients with lung cancer and observe the relationship of clinical stage,pathologic types,relation between CD4+CD25+ Treg and lung cancer.Methods Flow cytometer was used to analyze the level of CD4+CD25+ Treg in peripheral blood from seventy-eight cases of lung cancer patients and 30 cases of healthy donors.Results The proportion of CD4+CD25+ Treg in peripheral blood was significantly higher in lung cancer patients(21.07±5.26)%when compared with healthy donors(10.04±2.75)%(P＜0.05).The proportion of CD4+CD25+ Treg was significantly higher in stage Ⅲ or Ⅳ lung cancer patients(22.46±4.35)%,(24.35±6.20)% than in stage Ⅰ and Ⅱ lung cancer patients(12.89±3.19)% and healthy donors(P＜0.05).The proportion of CD4+CD25+ Treg was significantly higher in squamous cell carcinoma(20.75±4.85)%,adenocarcinoma(21.52±5.26)% and small cell lung cancer patients(19.20±6.41)% when compared with healthy donors(P＜0.05)but without significance among each teams(P＞0.05).The proportion of CD4+CD25+ Treg was significantly higher in high differentiation (20.36±3.12)%,middle differentiation(21.11±4.67)% and low differentiation(21.30±5.75)% lung cancer patients than in healthy donors(P＜0.05)but without significance among each teams(P＞0.05).Conclusion The proportion of CD4+CD25+ Treg in the peripheral blood of patients with lung cancer is significantly higher than healthy donors.It plays an importmant role in the progression of lung cancer.The up-regulation of CD4+CD25+Treg is not related with pathologic types.
